Registration Info

This is a 1-day meeting and will provide 6 CE/CME credits.

Conference Registration Fee

Practicing Healthcare Professionals: $129

This event has reached capacity and registration is closed.

Non-Clinicians / Medical Office Support Staff / Industry Participants

Non-clinicians--including, but not limited to, office managers, billing specialists, receptionists, and administrative staff--may attend PAINWeekEnd on a space-available basis when accompanied by a clinician and will be put on a wait list. These non-clinicians must still pre-register. Participation in industry sponsored meal programs, however, is strictly limited to practicing licensed healthcare providers. Please make necessary arrangements for meals for office support staff. In order to maintain the professional nature of the conference, guests, spouses, friends, and/or family members who are not currently employed in the medical field may not attend PAINWeekEnd.



Unfortunately, we do not have discounts available on hotel rooms. Please contact the hotel directly should you require accommodations.

Sheraton Agoura Hills
30100 Agoura Rd.
Agoura Hills, CA

Schedule (subject to change)

To view the schedule below, click on the + sign next to the day of the conference to expand the conference agenda. Click on the + signs within the agenda to view the course description, UAN number, and AANP pharmacology credits.

Saturday, December 8, 2018

  • Registration and Exhibits

    Coffee will be served.

  • A Comedy of Errors: Methadone and Buprenorphine

    The most contentious, poorly understood analgesics today are methadone and buprenorphine. This fast paced workshop will equip practitioners with immediately implementable practical tips regarding when and how to use these analgesics, including dosage formulations, routes of delivery, appropriate use in therapy, drug interactions, dosage titration (both up and down), opioid conversion calculations, and more. All discussions will be aimed at enhancing clinical, economic, and humanistic outcomes on the individual patient and health system level.

    • UAN: 0530-0000-18-032-L01-P
    • AANP Rx Hours: 1.0
  • Product, Disease Awareness, Medical Information Program*

    Breakfast will be served.

    Sponsored by AstraZeneca and Daiichi Sankyo Inc., Paul Choi, MD

  • Break & Exhibits

  • Recent Advances in Opioid Abuse Deterrent Formulations

    In 2017 the United States declared the opioid crisis as a public health emergency. The growing awareness of opioid related harms began much earlier and active efforts have been ongoing for over the last 10 years. Although the healthcare system has little impact on the illegal manufacturing, distribution, and abuse of illicit opioids, the healthcare system can positivity take steps to reduce the abuse of legitimate medical opioids. Many misconceptions exist regarding prescription opioid abuse and positive solutions will occur when specific problems are addressed, such as drug diversion and the way people abuse opioids. This course will review abuse mitigation strategies with particular focus on the technological enhancement to reduce abuse, especially the diversion, of prescription opioids, their process for obtaining FDA approval as abuse-deterrent opioids and a review of current and possible future technologies.

    This presentation is supported by an unrestricted educational grant from Daiichi-Sankyo, Inc.

    • UAN: 0530-0000-18-201-L01-P
    • AANP Rx Hours: 0.0
  • Get Your Specimens in Order: The Importance of Individualized Test Orders and Timely Test Utilization

    The government has ramped up its efforts in 2018 to connect claims of inappropriate opioid prescribing to financial gain, including gain from urine drug testing. While most physicians do not have a financial interest in a clinical laboratory, the government's decision to highlight an opioid prescriber's failure to timely utilize drug test results is significant, and suggests the government is looking at other factors tied to medical decision making. Thus, prescribers should pay attention to licensing board, payer, and professional society guidance on ordering drug tests and how to use drug test results when treatment involves opioid prescribing. Attendees will learn how to identify the core elements of medical necessity and document an individualized testing plan for each patient. This course will cover critical areas of medical record documentation, including the decision to drug test, when and how often; determining which drugs to test and why; and how to coordinate timely review and use of drug test results in connection with the patient's plan of care. Attendees will gain additional insight into these issues through position papers, published late 2017 and early 2018, by the American Academy of Pain Medicine and the American Association for Clinical Chemistry. The overall goal of the course is to assist prescribers in their quest to provide quality pain care to their patients and to document their rationale for drug testing and their treatment decisions.

    • UAN: 0530-0000-18-039-L01-P
    • AANP Rx Hours: 0.0
  • Faculty Q&A

  • Break & Exhibits

  • Product, Disease Awareness, Medical Information Program*

    Lunched will be served.

    Sponsored by SCILEX, Bill McCarberg, MD

  • IV Naloxone Infusion: A Hidden Gem

    Despite the current opioid crisis, opioids remain the mainstay of analgesic therapy. They are associated with a multitude of side effects, including respiratory depression, pruritus, nausea, vomiting, urinary retention, ileus, and constipation. Beyond certain doses and duration of intake that vary from patient to patient, opioids can also induce a state of paradoxical hyperalgesia. Among these side effects, opioid induced ileus, urinary retention, and opioid induced hyperalgesia contribute to unnecessary prolongation of hospital length of stay. Naloxone is a well known antagonist used to reverse opioid induced respiratory depression. There is evidence supporting the use of low dose IV naloxone to prevent and reverse all of the above mentioned opioid induced side effects without reversing the analgesia. However, low dose IV naloxone appears to be underutilized. In addition to reviewing the literature, we will share our experience and clinical results from the implementation of low dose IV naloxone protocols at Cedars Sinai Medical Center in Los Angeles.

    • UAN: 0530-0000-18-400-L01-P
    • AANP Rx Hours: 0.8
  • Break & Exhibits

  • Product, Disease Awareness, Medical Information Program*

    Refreshments will be served.

    Sponsored by Daiichi Sankyo Inc., Paul Choi, MD

  • Trainwreck: Addressing Complex Pharmacotherapy With the Inherited Pain Patient

    The prescription drug problem in America has led to many guidelines and, in some cases, regulations aimed at stemming the tide of prescription drug abuse. Some are evidence based, but most are driven by fear and an overwhelming need to do "something." Unfortunately, while these guidelines have offered suggestions of how to apply this information in a clinical context going forward, they provide little information as to the management of those patients who already exceed these current guidelines. This is where the concept of the "inherited patient" comes into play. Some of these patients are doing well while some are doing quite poorly. The undeniable fact is that as these guidelines are being exceeded, risk of a bad outcome increases while likelihood of achieving therapeutic goals decreases. This workshop will, through the use of representative cases, help participants to recognize irrational pharmacotherapy and, when necessary, address it through a combination of pharmacological as well as biopsychosocial frameworks.

    • UAN: 0530-0000-18-057-L01-P
    • AANP Rx Hours: 0.0
  • Embrace Changes and Mitigate Legal Risks Associated with Opioid Prescribing and the Issue of Overdose: An Updated Blueprint for the Pain Practitioner and Medical Directors

    Overdose--a small word that packs a major punch, and a big reason for many recent legal regulatory changes in controlled substance prescribing and pain management. Too many physicians and allied healthcare practitioners are caught unawares by the legal issues surrounding overdose events, fatal and nonfatal. Often, prescribers are the last to learn about an overdose event and, worse yet, fail to take action once notified. Through a series of case examples, attendees will learn how to develop and implement overdose event policies and protocols. Attendees will receive copies of sample policies and protocols and learn how to tailor them to their respective practices and state licensing board framework. Professional licensing board and criminal cases involving overdose events do not usually end well for the prescriber, but there is much the prescriber can do proactively to signal his/her intent to get things right. While prescribers cannot control what their patients do once they leave the medical office, they are responsible for establishing a safe framework for opioid prescribing, including a proper response when something goes wrong.

    • UAN: 0530-0000-18-045-L01-P
    • AANP Rx Hours: o.o


To accompany and enrich your experience at the PAINWeekEnd conference, be sure to attend one or more of the sponsored programs, which are scheduled during breakfast, lunch, and afternoon "Brain Food" time slots in the schedule. There is NO ADDITIONAL CHARGE to attend these program sessions!